Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT

NEW YORK, Aug. 7 NY-Keryx-Bio-Q2-call


NEW YORK, Aug. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
(Nasdaq: KERX) will hold a conference call on Monday, August 11, 2008 at 8:30
a.m. EDT to discuss the second quarter 2008 financial results. Michael S.
Weiss, Chairman and Chief Executive Officer of the Company, will host the
call. Keryx will announce its financial results for this period in a press
release to be issued prior to the call.


In order to participate in the conference call, please call 1-877-719-9788
(U.S.), 1-719-325-4769 (outside the U.S.), call-in ID: KERYX. The audio
recording of the conference call will be available for replay at
http://www.keryx.com, for a period of 15 days after the call.


The press release announcing our financial results for this period will be
posted on the Company's website, http://www.keryx.com, prior to the call.



About Keryx Biopharmaceuticals, Inc.


Keryx Biopharmaceuticals is focused on the acquisition, development and
commercialization of medically important, novel pharmaceutical products for
the treatment of life-threatening diseases, including renal disease and
cancer. Keryx is developing Zerenex(TM) (ferric citrate), an oral, iron-based
compound that has the capacity to bind to phosphate and form non-absorbable
complexes. Zerenex is currently in Phase 2 clinical development for the
treatment of hyperphosphatemia (elevated phosphate levels) in patients with
end-stage renal disease. The Company is also developing KRX-0401 (perifosine),
a novel, potentially first-in-class, oral anti-cancer agent that modulates
Akt, a protein in the body associated with tumor survival and growth. KRX-0401
also modulates a number of other key signal transduction pathways, including
the JNK and MAPK pathways, which are pathways associated with programmed cell
death, cell growth, cell differentiation and cell survival. KRX-0401 is
currently in Phase 2 clinical development for multiple tumor types. The
Company also has an in-licensing and acquisition program designed to identify
and acquire additional drug candidates. Keryx is headquartered in New York
City.



 Contact:  Lauren Fischer, +1-212-531-5965



SOURCE  Keryx Biopharmaceuticals, Inc.